CYGB

Across TCGA pan-cancer cohorts, CYGB mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYGB data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CYGB mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CYGB expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where CYGB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.994	0.569	.002	35	view →
LUAD	OS	Median	III,IV	0.295	0.912	.003	25	view →
CCRCC	DFS	Median	III,IV	0.764	0.408	.003	21	view →
LSCC	OS	Median	All	0.918	1.000	.005	15	view →
GBM	DFS	Quartile	All	0.867	0.514	.010	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYGB–PDAC (OS)

Open the PDAC breakdown →